TECH OUTLOOK 6JULY 2024EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comContract research organizations (CRO) are embracing a new wave of tools and approaches that are transforming how clinical trials are conducted. From leveraging artificial intelligence to designing decentralized trials, these advancements are leading to more efficient, data-driven, and patient-centric research. Decentralized clinical trials (DCTs) are transforming the CRO industry by utilizing telemedicine, wearables and electronic patient-reported outcomes (ePRO) to enable remote participation and continuous data collection. This approach improves data quality, boosts patient involvement and cuts costs by reducing logistical barriers. DCTs enhance the patient experience and promise a more inclusive, efficient future for clinical research as these technologies advance. Another technological trend is Generative AI transforming drug discovery and reshaping R&D with ML and NLP algorithms. It accelerates clinical trials, predicts bioactivity and toxicity, and guides drug development for cancer, Alzheimer's, arthritis, fibrosis, and rare diseases. Various firms, including CROs, CDMOs, and leading pharma companies, are leveraging GenAI to pioneer advancements in drug development.Driven by these trends, the global CRO market is projected to grow to approximately $118.81 billion by 2033, with a CAGR of 6.92 percent.This edition of the Pharma Tech Outlook offers insights into the latest trends in pharmaceutical technology and how companies are aligning with these trends. Stay informed as industry leaders share their experiences and strategies for navigating the evolving landscape of healthcare technology standards and the growing demand for more user-friendly practices. The magazine features a thought-provoking article from Chow Woai Sheng, Vice President of Global Instrument Manufacturing and Singapore General Manager of Agilent Technologies. He sheds light on pharmaceutical manufacturers boosting competitiveness and resilience amid global crises by adopting large-scale 4IR technologies for smarter, sustainable production. It also includes an article by Michael Shim, National Director of Medical Affairs at Syneos Health, Larry Dollar, Vice President Medical Affairs at Syneos Health and Drew Beck, Head of Strategy, Growth, and Innovation at Syneos Health.In this edition of Pharma Tech Outlook, we also feature the Top CROs 2024 We hope you find the right partner to meet your organization's needs. Let us know your thoughts!CRO Market Boom with AI Advancements TECH OUTLOOKCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.TECH OUTLOOKJULY - 01 - 2024, Vol 10 - Issue 08 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: * Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:VisualizerHenry SmithParley Meadow
< Page 5 | Page 7 >